All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
MHRA Drug Safety Update November 2013 advises that the use of short-acting β2 agonists (SABAs) for tocolysis in premature labour has been restricted to 48 hours maximum parenteral use under specialist supervision, after a European safety review. Oral SABAs should not be used in any obstetric indication.